Weiwei Wang, Ph.D.

Postdoctoral Research Fellow

Education: Biological Sciences (BA), Xiamen University (China); Biochemistry and Molecular Biology (MS), Xiamen University (China); Pharmacology and Physiology, Rutgers Biomedical and Health Sciences; Postdoc scholar, Ophthalmology Dept, UCSF

Research Project: Gene therapy for Usher Syndromes (Retina)

Research Interest: translating photoreceptor pathophysiology to therapeutic intervention

Career Ambition: contribute to the innovation of therapeutic strategies for vision and retinal disorders

Awards and Honors:

  • Best Poster Award for 2013 GSA Research Symposium, from the Graduate School of Biomedical Sciences, Rutgers- Biomedical and Health Sciences, Newark, NJ
  • Graduate Student Travel Award for Experimental Biology 2013 Meeting, from the American Society for Pharmacology & Experimental Therapeutics
  • Excellent Graduate Thesis, Xiamen University 2005

 

 

Vandenberghe Lab Team

Eric Zinn, BA

Systems Biology Graduate Student

Education: B.A. – Biological Sciences, Northwestern University, Evanston, IL, 2008-2012

Research Project: Engineering novel AAV Capsids for Gene Therapy; Investigating nature of amino acid interactions in the AAV capsid using evolution; Multiplexed analysis of protein libraries; In silico prediction of useful AAV mutants.

Research Interest: Allowing theory, computation, and experiment to influence each other in pursuit of scientific discovery.  Also, I like pretty charts.

Career Ambition: Convince a benevolent billionaire to fund moon-shot projects regarding synthetic life

Membership: AAAS, ASV, ASGCT

Awards and Honors: C.J. Luther Scholar 2011-2012, J.G. Nolan Scholar, 2010-2012, Herchel Smith Graduate Fellowship, 2015-Present

Vandenberghe Lab Team

Luk H. Vandenberghe, PhD

Director

Luk H. Vandenberghe, PhD, is an Associate Professor at Harvard Medical School and Associate Member of the Broad Institute of Harvard and MIT in Boston, MA, USA. He directs the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear Infirmary in Boston, USA, a part of the the Ocular Genomics Institute, a bench to bedside research program to study, diagnose, and develop treatments for diseases of the eye.

He received a degree in cellular and genetic engineering from the University of Leuven, Belgium. His previous work led to the discovery of novel AAV serotypes such as AAV9, novel insights into AAV structure-function, and vector immunobiology. His laboratory aims to gain a deeper understanding of mechanisms of gene transfer, to develop technologies to overcome hurdles to gene therapy clinical applications, and to translate specific gene therapy programs in vision, hearing, and other fields. Recent studies leverage structural and evolutionary information on AAV as a starting point for the rational design of synthetic viral vector systems, a first generation of which is referred to as AncAAVs which are now progressing to the clinic for a number of indications. Dr. Vandenberghe previously co-founded GenSight Biologics and Akouos. He also is a founder, board member, and advisor to Odylia Therapeutics, a non-profit catalyzing translation for gene therapies within the challenging field of ultra-rare disorders. Dr. Vandenberghe has over 50 peer reviewed publication and more than a dozen licensed patents, mostly related to gene therapy methods, technologies, and applications.

Vandenberghe Lab Team

© 2018 Grousbeck Gene Therapy Center

20 Staniford Street, Boston, MA 02114